Group items matching

in title, tags, annotations or url

ASDS has taken a prospective approach to positively affecting the future of the specialty of dermatologic surgery in recommending research on Board-directed topics. The intended result of Board-directed research is data that will help promote dermatologic surgeons as innovators, foster public awareness of dermatologic surgeons as experts, support ASDS positions on patient safely and regulatory issues, etc. Evidence-based and comparative effectiveness research is called for as well. By facilitating research in specific areas, ASDS will be able to further position itself as a catalyst for key findings in dermatologic surgery, and you can play an integral role.

ASDS has taken a prospective approach to positively affecting the future of the specialty of dermatologic surgery in recommending research on Board-directed topics. The intended result of Board-directed research is data that will help promote dermatologic surgeons as innovators, foster public awareness of dermatologic surgeons as experts, support ASDS positions on patient safely and regulatory issues, etc. Evidence-based and comparative effectiveness research is called for as well. By facilitating research in specific areas, ASDS will be able to further position itself as a catalyst for key findings in dermatologic surgery, and you can play an integral role.

This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing research on the use of current and emerging technologies for monitoring of blood glucose levels to capture the relationship between blood glucose excursions, perception of wellbeing, and cognitive status in people with type 1 diabetes (T1D). This information will inform the design of more effective interventions that may improve patient reported outcomes (PROs), including quality of life measures, and validate glycemic measures that may serve as outcomes in clinical trials to improve glucose management in T1D.

The Michael J. Fox Foundation believes that a major hurdle in the development of promising treatments for Parkinson's disease is the need for well-validated targets linked to the disease process. By promoting critical target validation studies within academic and industry laboratories, MJFF investments can help de-risk subsequent drug development and ultimately accelerate the creation of innovative therapies for Parkinson's patients. Part of our Edmond J. Safra Core Programs for PD Research, the Target Advancement program seeks to build robust evidence to rationalize biological pathways and targets for further translation into new Parkinson's treatments.

The Michael J. Fox Foundation believes that a major hurdle in the development of promising treatments for Parkinson's disease is the need for well-validated targets linked to the disease process. By promoting critical target validation studies within academic and industry laboratories, MJFF investments can help de-risk subsequent drug development and ultimately accelerate the creation of innovative therapies for Parkinson's patients. Part of our Edmond J. Safra Core Programs for PD Research, the Target Advancement program seeks to build robust evidence to rationalize biological pathways and targets for further translation into new Parkinson's treatments.

This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing research on the use of current and emerging technologies for monitoring of blood glucose levels to capture the relationship between blood glucose excursions, perception of wellbeing, and cognitive status in people with type 1 diabetes (T1D). This information will inform the design of more effective interventions that may improve patient reported outcomes (PROs), including quality of life measures, and validate glycemic measures that may serve as outcomes in clinical trials to improve glucose management in T1D.

The aim of the CDA is to support the next generation of researchers and to significantly improve outcomes and quality of life for breast cancer patients. The award will provide up to $100,000 per year for two years to be combined with matching funds or in kind contribution from the applicant's institution. Neither ASTRO nor BCRF will pay indirect costs as part of this award. One award will be funded. Research must be focused on understanding or treatment of breast cancer and include use or impact of radiation treatment.

The aim of the CDA is to support the next generation of researchers and to significantly improve outcomes and quality of life for prostate cancer patients. The award will provide up to $75,000 per year for three years to be combined with matching funds or in kind contribution from the applicant's institution. Neither ASTRO nor PCF will pay indirect costs as part of this award. One award will be funded. Research must be focused on understanding or treatment of prostate cancer and include use or impact of radiation treatment.

This R18 Request for Application (RFA) calls for the creation and utilization of Patient Safety Learning Laboratories. These learning laboratories are places and networks where transdisciplinary teams identify closely related threats to diagnostic or treatment efforts associated with a high burden of harm and cost. Following a systems engineering methodology, the learning laboratories stretch professional boundaries, envision innovative designs, and take advantage of brainstorming and rapid prototyping techniques that other leading industries employ. Promising prototypes undergo further develop-test-revise iterations, and subsequent integration as a working system. After further improvements are made to the integrated working system, its efficacy is evaluated in a realistic simulated or clinical setting. While applicants will select the area of diagnostic or treatment focus they consider of high significance, a flexible methodology -- problem analysis, design, development, implementation, and evaluation -- is required that parallels a systems engineering process to give an underlying structure to the work undertaken.

This funding opportunity announcement (FOA) solicits applications for Minority PDX (minority patient-derived xenografts) Development and Trial Centers (M-PDTCs). The M-PDTCs will join the PDTC Research Network (PDXNet) and be focused upon development and pre-clinical testing of models derived from racial/ethnic minority populations. The PDXNet is a National Cancer Institute (NCI) program established to coordinate collaborative, large-scale model development and pre-clinical testing of targeted therapeutic agents to advance the vision of cancer precision medicine.

This funding opportunity announcement (FOA) solicits applications for Minority PDX (minority patient-derived xenografts) Development and Trial Centers (M-PDTCs). The M-PDTCs will join the PDTC Research Network (PDXNet) and be focused upon development and pre-clinical testing of models derived from racial/ethnic minority populations. The PDXNet is a National Cancer Institute (NCI) program established to coordinate collaborative, large-scale model development and pre-clinical testing of targeted therapeutic agents to advance the vision of cancer precision medicine.

The PRMRP Technology/Therapeutic Development Award (TTDA) is a product-driven award intended to provide support for the translation of promising preclinical findings into products for clinical applications, including prevention, detection, diagnosis, patient care, and/or quality of life, in at least one of the Congressionally directed FY13 PRMRP Topic Areas. Products in development should be responsive to the health care needs of military service members,Veterans, and/or beneficiaries. The product(s) to be developed may be pharmacologic agents (drugs or biologics), devices, and/or clinical guidance for standard of care. The Principal Investigator (PI) must provide a transitio

Shwachman-Diamond Syndrome Foundation (SDSF) is a nonprofit support organization actively helping the victims of this disease. SDSF is accepting grant requests for research relevant to this disease. Any high quality, innovative research proposal deemed relevant to SDS will be considered. The following are areas of particular interest: Investigate or evaluate potential novel therapies or potential novel therapeutic strategies- preferred applications Evaluate predictors of bone marrow abnormalities to determine their correlation with the disease Determine the causes of and investiagte treatments for bone marrow failure and leukemia Evaluate protocols and regimens for bone marrow transplants Evaluate causes and investigate treatments for graft vs host disease and other infections of post bone marrow transplants Investigations related to adult patient presentation, management, and care including transition from pediatric-centered to adult care

The purpose of this FOA is to provide support for innovative research into the role of extracellular RNA (exRNA) in the development of alcohol-related diseases and end-organ injuries. As used here, the term exRNA refers to RNA molecules circulating outside of cells, either within vesicles or associated with carrier molecules. It is anticipated that this FOA will generate data that may lead to breakthroughs in our understanding of the role of exRNA communication in the initiation, progression and maintenance of the diverse medical disorders caused by excessive, long-term alcohol consumption. In the future this knowledge may be critical in the diagnosis, treatment and management of vulnerable patient populations debilitated by the vast array of alcohol-induced pathologies and enable clinicians to improve disease outcomes and, consequently, public health. In addition, research supported by this FOA may also provide information on the mechanistic basis of the health benefits of moderate alcohol consumption.

The OCRP Teal Innovator Award supports a visionary individual from any field principally outside of, but not exclusive of, ovarian cancer to focus his/her creativity, innovation, and leadership on ovarian cancer research. The Teal Innovator Award will provide the Principal Investigator (PI) with the funding and freedom to pursue his/her most novel, visionary, high-risk ideas that could significantly impact the field of ovarian cancer research or patient care. The proposed Teal Innovator must be highly recognized in his/her field and present evidence of this recognition. Examples include, but are not limited to, recognition at the level of endowed chair; membership in the National Academy of Sciences, National Academy of Engineering, or Institute of Medicine; Chairmanship of the American Association for Cancer Research; or other national or international recognition.

The Children's Fund for Glycogen Storage Disease Research accepts grant applications that relate to GSD1 research, diagnosis, and/or patient care.

Research!America is pleased to announce an exciting new program to introduce and engage early-career scientists in research advocacy and science policy. The 2013 Research!America Advocacy Academy is a unique opportunity for postdoctoral fellows in the health and biomedical sciences to learn about how to best incorporate advocacy and effective communications into their role as a scientist. The 2013 class of up to 12 Research!America advocates will participate in a two-day Washington, DC, program from September 11-12, 2013. Participants will learn about the federal budget and appropriations process, tools for effective science communication and outreach as well as how to engage with elected representatives on scientific and research issues. The program includes visiting Capitol Hill to meet with policy makers and congressional staff members, providing participants with a first-hand experience advocating for health research. Rounding out this unique Washington experience, participants will attend Research!America's National Health Research Forum where top leaders in government, industry, academia and patient organizations engage in moderated conversations on issues of importance to the research ecosystem. Upon completion of the program, participants will become Science Advocates for Research!America. Advocates will remain engaged with Research!America staff, receive ongoing action alerts and learn about ways to involve their home institution's research community in effective science advocacy. All travel expenses (transportation, lodging and meals) will be provided and arranged by Research!America through an educational grant provided by Pfizer. This year's program is limited to 12 exceptional postdoctoral researchers with a dedicated interest in becoming active advocates for science.

The Investigator-Initiated Translational Research Award (IITRA) supports translational research that will develop promising ideas in lung cancer into clinical applications. Translational research may be defined as an integration of basic science and clinical observations. Observations that drive a research idea may originate from a laboratory discovery, population-based studies, or a clinician's firsthand knowledge of patient care. The ultimate goal of translational research is to move a concept or observation forward into clinical application. However, Principal Investigators (PIs) should not view translational research as a one-way continuum from bench to bedside. The research plan must involve a reciprocal flow of ideas and information between basic and clinical science. This mechanism is intended to fund a broad range of translational studies, including, but not limited to, the following: * Studies advancing/translating in vitro and/or animal studies to applications with human samples/cohorts. * Late-stage preclinical work leading to/preparing for a clinical trial, e.g., Investigational New Drug (IND) application submission. * Correlative studies that are associated with an ongoing or completed clinical trial and projects that develop endpoints for clinical trials. Preliminary data to support the feasibility of the research hypotheses and research approaches are required; however, these data do not necessarily need to be derived from studies of lung cancer.

This Funding Opportunity Announcement (FOA) invites applications for the Morris K. Udall Centers of Excellence for Parkinson's Disease Research program. The overarching goal of the specialized Udall Centers program is to establish a network of Centers that work collaboratively as well as independently to define the causes of and discover improved treatments for Parkinson's disease (PD). A more immediate goal for each Center is to rapidly advance synergistic, interdisciplinary research programs while serving as national leaders in PD research. Udall Centers also serve as local resources by organizing research career enhancement activities for Center investigators and periodic outreach to the PD patient/advocacy community. Applicants are expected to identify and address an overall research theme that defines a critical challenge in PD research. The stated theme, proposed research projects, and associated cores will inform the etiology, pathogenesis or treatment of PD; investigations on related synucleinopathies may be included if such studies directly address the identified PD research challenge.

The primary purpose of the ASRM and SREI Research Grant Programs is to provide funds for new investigators to establish independent research programs. New investigators are those who have completed their training within the past three years and have independent faculty appointments at the commencement of the research. In special cases, ASRM will consider applications for bridge funding (i.e., between grant funding periods) for projects that are of benefit to other members of the Society, or for funding of new, highly innovative research projects by established investigators. Both the ASRM Research Grants, which are funded by the ASRM, and the SREI Research Grants, which are funded by SREI, are reviewed by the ASRM Research Committee. Grants in amounts of $10,000 to $50,000 will be considered for funding by the ASRM Board of Directors on an annual basis. A total of $200,000 is available for 2016. The SREI Board of Directors will fund one grant of up to $40,000. Funds are available for project expenses, technical assistance, patient expenses, research supplies and durable laboratory equipment. Up to ten percent (10%) of funds may be used for indirect costs or institutional overhead in circumstances deemed to be extraordinary by the Research Committee. Research grant funds may be expended over a 2-year time interval. If residual funds remain after 2 years, the principal investigator can apply for a no-cost extension. An individual should indicate which grant(s) he/she is applying for though he/she is eligible to receive only one grant.

The Aniara Research Panel awards one yearly grant for specialized in hematology and coagulation research. All proposed projects must be in the coagulation/hematology scientific field. This year, the sponsor is asking for projects that deal specifically with EDS - Ehlers-Danlos syndrome - and its effects on hemostasis and thrombosis. Extensive bruising, spontaneous arterial rupture, rupture of hollow organs, and severe internal bleeding are predominant features in EDS. Patients suffering from such syndromes typically undergo hematological studies including evaluation of clotting factors, platelet aggregation, and bleeding time.

To promote the development of successful independent researchers working to improve the care of patients with serious illness, the NPCRC is requesting applications for its Transition to Independence Award (TIA). The aim of the TIA is to expand the cadre of palliative care researchers by extending research support to promising investigators completing a federal career development award whom have not yet achieved independence as measured by successful receipt of an NIH R01 award or equivalent. The TIA assures a continuum of support for turning promising junior investigators into independent researchers.